For life's uncertain moments...

We are dedicated to the prevention and treatment of tetanus

Stock up on HyperTET now



HyperTET ® (tetanus immune globulin [human]) is manufactured and distributed by **Grifols**, a global provider of plasma-derived therapies since the company's founding in **1909**.

Tetanus remains a rare, but life-threatening, disease in the **United States.**
It kills about **1** out of **10** people who are infected.[1]

Provide immediate protection with **HyperTET** [2,3]

Trusted Dependability

- Established history—more than 45 years of consistent supply and product support[3]
- Not made with Mercury (thimerosal) or natural rubber latex
- US Food and Drug Administration (FDA) labeling for capacity to remove pathogenic prions
- Convenient prefilled syringes with BD UltraSafe® Needle Guards* to protect against needlestick injury
- Tamper-evident packaging

*BD UltraSafe® Needle Guard is a registered trademark of Becton, Dickinson and Company.

HyperTET® is made from human blood and may carry a risk of transmitting infectious agents, eg, viruses, the vCJD agent, and theoretically, the CJD agent.

HyperTET is available through all major distributors.

Please see Important Safety Information below for HyperTET® (tetanus immune globulin [human]).

Important Safety Information

HyperTET® (tetanus immune globulin [human]) is indicated for prophylaxis against tetanus following injury in patients whose immunization is incomplete or uncertain.

HyperTET should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations.

In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HyperTET should be given only if the expected benefits outweigh the risks.

Slight soreness at the site of injection and slight temperature elevation may be noted at times. Sensitization to repeated injections of human immunoglobulin is extremely rare. In the course of routine injections of large numbers of persons with immunoglobulin, there have been a few isolated occurrences of angioneurotic edema, nephrotic syndrome, and anaphylactic shock after injection. Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after tetanus immune globulin (human) administration.

HyperTET is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

Please see full Prescribing Information for HyperTET.

References: 1. Centers for Disease Control and Prevention. Diphtheria, tetanus, and pertussis vaccine safety. http://www.cdc.gov/vaccinesafety/vaccines/dtap-tdap-vaccine.html. Updated March 6, 2023. Accessed March 17, 2023.
2. HyperTET (tetanus immune globulin [human]) Prescribing Information. **3.** Data on file. Grifols.

Contact Information: {{Sender.name}} {{Sender.phone}} / Email
Medical Information 1.800.520.2807

GRIFOLS

HyperTET®
Tetanus Immune Globulin (Human)